Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition
Pacira BioSciences Inc (NASDAQ:PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ:FLXN) for $8.50 per share in cash, plus one contingent value…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
Flexion Therapeutics Reports Inclusion Of ZILRETTA In American Academy Of Orthopaedic Surgeons Clinical Practice Guidelines For Mgmt. Of Osteoarthritis Of The Knee
Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based
54 Biggest Movers From Yesterday
Gainers
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently reported partial exercise of underwriter’s over-allotment option.
Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?
Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy.
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a
60 Biggest Movers From Yesterday
Gainers
Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.